| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Divisions of Cellular and Molecular Biology [J. D., M. B., S. K-R., L. Z. P.] and Experimental Therapeutics [L. Y. Y., M. J. M.], Ontario Cancer Institute, University Health Network, Toronto, Ontario, M5G 2M9 Canada; Departments of Paediatric Laboratory Medicine [H. Y.] and Haematology [M. H. F.], The Hospital for Sick Children, Toronto, Ontario, Canada; Departments of Medical Biophysics [M. B., L. Z. P.], Pharmaceutical Sciences [L. Y. Y., M. J. M.], and Laboratory Medicine and Pathobiology [S. K-R., H. Y.], University of Toronto, Toronto, Ontario, Canada
3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase is the rate-limiting enzyme of the mevalonate pathway, the diverse array of end products of which are vital for a variety of cellular functions, including cholesterol synthesis and cell cycle progression. We showed previously that this enzyme holds a critical role in regulating tumor cell fate, including cell death, as its expression is down-regulated in response to retinoic acid, a potent anticancer therapeutic. Indeed, direct inhibition of HMG-CoA reductase with lovastatin, a competitive inhibitor of this enzyme, induced a pronounced apoptotic response in neuroblastoma and acute myeloid leukemic cells. We have now extended this work and evaluated a wide variety and large number of tumor-derived cell lines for their sensitivity to lovastatin-induced apoptosis. These cell lines were exposed to a wide range (0–100 µM) of lovastatin for 2 days and assayed for cell viability using the 3,4,5-dimethyl thiazlyl-2,2,5-diphenyltetrazolium bromide assay and the induction of apoptosis by flow cytometric and ultrastructural analyses. Lovastatin induced a pronounced apoptotic response in cells derived from juvenile monomyelocytic leukemia, pediatric solid malignancies (rhabdomyosarcoma and medulloblastoma), and squamous cell carcinoma of the cervix and of the head and neck. Interestingly, the subset of malignancies that are particularly sensitive to lovastatin-induced apoptosis correspond to those tumor subtypes that are sensitive to the biological and antiproliferative effects of retinoids in vitro. The nature of the biologically active form of lovastatin has been challenged recently as the growth-inhibitory effects of this drug were attributed to its prodrug lactone form that does not inhibit HMG-CoA reductase function. In this report, we demonstrate that the apoptotic properties of lovastatin are triggered by the open ring acid form that is a potent inhibitor of HMG-CoA reductase activity. Thus, we have identified a subset of tumors that are sensitive to lovastatin-induced apoptosis and show HMG-CoA reductase as a potential therapeutic target of these cancers.
This article has been cited by other articles:
|
|
 |
|
  J. Woodard, A. Sassano, N. Hay, and L. C. Platanias Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2008; 14(14): 4640 - 4649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Niknejad, M. Morley, and J. Dimitroulakos Activation of the Integrated Stress Response Regulates Lovastatin-induced Apoptosis J. Biol. Chem., October 12, 2007; 282(41): 29748 - 29756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Roelofs, C. M. Edwards, R. G. G. Russell, F. H. Ebetino, M. J. Rogers, and P. A. Hulley Apomine Enhances the Antitumor Effects of Lovastatin on Myeloma Cells by Down-Regulating 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 228 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma Mol. Cancer Ther., June 1, 2007; 6(6): 1886 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, and L. C. Platanias Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells Cancer Res., May 1, 2007; 67(9): 4524 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Sivaprasad, T. Abbas, and A. Dutta Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2310 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dimitroulakos, I. A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin. Cancer Res., July 15, 2006; 12(14): 4426s - 4431s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nubel, J. Damrot, W. P. Roos, B. Kaina, and G. Fritz Lovastatin Protects Human Endothelial Cells from Killing by Ionizing Radiation without Impairing Induction and Repair of DNA Double-Strand Breaks Clin. Cancer Res., February 1, 2006; 12(3): 933 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Z. Carter, M. Gronda, Z. Wang, K. Welsh, C. Pinilla, M. Andreeff, W. D. Schober, A. Nefzi, G. R. Pond, I. A. Mawji, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells Blood, May 15, 2005; 105(10): 4043 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells Carcinogenesis, May 1, 2005; 26(5): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Mantha, J. E.L. Hanson, G. Goss, A. E. Lagarde, I. A. Lorimer, and J. Dimitroulakos Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor Clin. Cancer Res., March 15, 2005; 11(6): 2398 - 2407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wu, W. W.-L. Wong, F. Khosravi, M. D. Minden, and L. Z. Penn Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis Cancer Res., September 15, 2004; 64(18): 6461 - 6468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Graaf, A. B. Beiderbeck, A. C.G. Egberts, D. J. Richel, and H.-J. Guchelaar The Risk of Cancer in Users of Statins J. Clin. Oncol., June 15, 2004; 22(12): 2388 - 2394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kim, R. M. Adam, K. R. Solomon, and M. R. Freeman Involvement of Cholesterol-Rich Lipid Rafts in Interleukin-6-Induced Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells Endocrinology, February 1, 2004; 145(2): 613 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nath, S. Giri, R. Prasad, A. K. Singh, and I. Singh Potential Targets of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for Multiple Sclerosis Therapy J. Immunol., January 15, 2004; 172(2): 1273 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shaukat, M. Benekli, G. D Vladutiu, J. L Slack, M. Wetzler, and M. R Baer Simvastatin-Fluconazole Causing Rhabdomyolysis Ann. Pharmacother., July 1, 2003; 37(7): 1032 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Li, F. R. Appelbaum, C. L. Willman, R. A. Zager, and D. E. Banker Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses Blood, May 1, 2003; 101(9): 3628 - 3634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. W. Chan, A. M. Oza, and L. L. Siu The Statins as Anticancer Agents Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Edinger and C. B. Thompson Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient Uptake Mol. Biol. Cell, July 1, 2002; 13(7): 2276 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W.-L. Wong, M. M. Tan, Z. Xia, J. Dimitroulakos, M. D. Minden, and L. Z. Penn Cerivastatin Triggers Tumor-specific Apoptosis with Higher Efficacy than Lovastatin Clin. Cancer Res., July 1, 2001; 7(7): 2067 - 2075. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
